-
2026 Pujiang Urologic Oncology Academic Conference | Professor Xiaojie Bian: ADCs Across the Entire Urothelial Carcinoma Treatment Continuum—Balancing Sequencing and Safety, From Earlier-Line Treatment to Cross-Payload Sequencing Strategies
The 2026 Pujiang Urologic Oncology Academic Conference was held in Shanghai. The rapid development of antibody–drug conjugates (ADCs) and immunotherapy is moving the treatment of urothelial carcinoma beyond later-line advanced disease to first-line treatment, the perioperative setting, and even non-muscle-invasive disease. At the same time, the clinical introduction of ADCs with multiple targets and payloads…
-
CACA GU | Professor Zhenghua Ju: Overcoming the Challenges of Precise Laparoscopic Suturing—From the Challenges of Vesicourethral Anastomosis and the 360° Suturing Theory to the Three Fundamental Principles of Surgical Suturing
Precise suturing is a key foundation for high-quality reconstruction in minimally invasive surgery. During laparoscopic radical prostatectomy, vesicourethral anastomosis tests the surgeon’s ability to control needle-holding angles and needle trajectories, while directly affecting procedural stability and reproducibility. In this interview, Oncology Frontier – UroStream invited Professor Zhenghua Ju of Fujian Cancer Hospital to discuss the…
-
Professor Hongkai Wang: Advancing Robotic Radical Prostatectomy Through Technical Innovation to Preserve Both Cancer Control and Function | Pujiang Prostate Cancer Academic Conference
The 2026 Pujiang Prostate Cancer Academic Conference was successfully held in Shanghai under the central theme of “Standardization, Precision Breakthroughs, Chinese Innovation, and Global Collaboration.” The conference aimed to promote the standardized diagnosis and treatment of prostate cancer in China while advancing key technological innovations. Following the meeting, Oncology Frontier – UroStream invited Professor Hongkai…
-
CACA GU | Professor Xiang Li: From Clinical Risk Stratification to Molecular Subtyping—A New Pathway to Precision Treatment for Advanced Renal Cell Carcinoma
Treatment decisions for advanced renal cell carcinoma (RCC) are shifting from traditional clinical risk stratification toward precision classification based on molecular characteristics. What is the scientific rationale behind this trend? Which key molecular biomarkers hold the greatest promise for guiding treatment selection and sequencing? And what are the major obstacles to translating scientific discoveries in…
-
CACA GU | Professor Zhuowei Liu: Advancing Standardized Urologic Oncology Care from Prevention to Comprehensive Management
Approximately 101,000 new cases of bladder cancer are diagnosed annually in China, making it the 11th most common malignancy. The disease is more prevalent in southern China than in the north, and its incidence is trending toward younger age groups. Meanwhile, high-risk localized or locally advanced prostate cancer carries a substantial risk of biochemical recurrence…
-
CSCO 2026 | Professor Xinan Sheng: Clinical Insights from 3.5-Year Follow-Up of the EV-302 Trial—Long-Term Survival Benefits and Treatment Continuity
Platinum-based chemotherapy has historically been the standard first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC), but long-term survival outcomes have remained poor. There is an urgent clinical need for first-line regimens that offer high efficacy and sustained disease control. The EV-302 trial directly compared enfortumab vedotin plus pembrolizumab with standard platinum-based chemotherapy. Earlier…
-
2026 Cross-Strait Hematology Academic Conference | Huiju Tsai: Empowering Transplant Care with the TBMT APP and Advancing Nursing Development Through Cross-Strait Collaboration
In the golden autumn season, experts from across the Taiwan Strait gathered in Zhuhai. The 2026 Cross-Strait Hematology Academic Conference was held in Zhuhai, Guangdong, on August 21–22, bringing together hematology experts and scholars from both sides of the Taiwan Strait, as well as Hong Kong and Macao, for in-depth discussions on cutting-edge developments, clinical…
-
2026 Cross-Strait Hematology Academic Conference | Dr. Sheng‑Hsuan Chien: From Taiwan’s Experience to Precision Transfusion—Exploring the Path Forward for Patient Blood Management (PBM)
Transfusion medicine is an essential foundation for the diagnosis and treatment of hematologic diseases, and its underlying philosophy is undergoing a profound transformation from a “blood-centered” to a “patient-centered” approach. As the field advances standardized blood utilization and transfusion safety, how to establish a scientific blood management system and implement precision transfusion strategies remains a…
Connecting Medical Expertise through Media